Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study

被引:38
|
作者
Saari, T. I. [1 ,2 ,3 ]
Ihmsen, H. [1 ]
Neuvonen, P. J. [4 ]
Olkkola, K. T. [2 ,3 ]
Schwilden, H. [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nuremberg, Dept Anaesthesiol, D-91054 Erlangen, Germany
[2] Univ Turku, Dept Anaesthesiol Intens Care Emergency Care & Pa, Turku, Finland
[3] Turku Univ Hosp, FIN-20520 Turku, Finland
[4] Univ Helsinki, Dept Clin Pharmacol, Cent Hosp, SF-00250 Helsinki, Finland
关键词
analgesics; opioid; intravenous; elderly; oxycodone; population pharmacokinetics; CONTROLLED-RELEASE OXYCODONE; ORAL OXYCODONE; INTRAVENOUS OXYCODONE; MODEL; CYP2D6; PHARMACODYNAMICS; TRANSPLANTATION; INHIBITION; EXPOSURE; MORPHINE;
D O I
10.1093/bja/aer395
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Oxycodone is a -opioid receptor agonist, the global use of which has increased vigorously during the past decade. The pharmacokinetic data of oxycodone available for elderly are limited, and there appear to be only little data on the population pharmacokinetics of oxycodone. We analysed 1272 plasma oxycodone samples of 77 individuals (range of age 1989 yr) with non-linear mixed effect modelling. Inter- and intra-individual variability of the model was estimated for clearances and distribution volumes. The effect of covariates was studied with simulations. Data were best described with a two-compartment linear model. Lean body mass and age were found to be significant covariates for elimination clearance and the volume of the central compartment. The population estimates of elimination clearance, volume of the central compartment, and the volume of distribution at steady state for a reference individual (male 35 yr, 70 kg, 170 cm) were 51.0 litre h(1), 134, and 258 litres, respectively. The elimination half-life of oxycodone showed an age-dependent increase. The context-sensitive half-time at steady state increased from 3.8 to 4.6 h between the age of 25 and 85 yr, respectively. Simulations of repetitive bolus dosing showed a 20 increase in oxycodone concentration in the elderly. Age was found to be a significant covariate for oxycodone pharmacokinetics. In elderly patients, dosing should therefore be reduced and carefully titrated to avoid considerable accumulation of oxycodone and potentially hazardous side-effects.
引用
收藏
页码:491 / 498
页数:8
相关论文
共 50 条
  • [1] Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials
    Valitalo, Pyry
    Kokki, Merja
    Ranta, Veli-Pekka
    Olkkola, Klaus T.
    Hooker, Andrew C.
    Kokki, Hannu
    PHARMACEUTICAL RESEARCH, 2017, 34 (05) : 1125 - 1133
  • [2] Elimination of Intravenous Oxycodone in the Elderly A Pharmacokinetic Study in Postoperative Orthopaedic Patients of Different Age Groups
    Liukas, Antti
    Kuusniemi, Kristiina
    Aantaa, Riku
    Virolainen, Petri
    Neuvonen, Mikko
    Neuvonen, Pertti J.
    Olkkola, Klaus T.
    DRUGS & AGING, 2011, 28 (01) : 41 - 50
  • [3] A Population Pharmacokinetic and Pharmacodynamic Study of a Peripheral κ-Opioid Receptor Agonist CR665 and Oxycodone
    Olesen, Anne E.
    Kristensen, Kim
    Staahl, Camilla
    Kell, Sherron
    Wong, Gilbert Y.
    Arendt-Nielsen, Lars
    Drewes, Asbjorn M.
    CLINICAL PHARMACOKINETICS, 2013, 52 (02) : 125 - 137
  • [4] Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study
    Kurata, Yasuo
    Muraki, Shota
    Hirota, Takeshi
    Araki, Hiroshi
    Ieiri, Ichiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 41
  • [5] Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers
    Ladebo, Louise
    Foster, David J. R.
    Abuhelwa, Ahmad Y.
    Upton, Richard N.
    Kongstad, Kenneth T.
    Drewes, Asbjorn M.
    Christrup, Lona L.
    Olesen, Anne E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 (03) : 263 - 276
  • [6] Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
    Royer, B.
    Kalbacher, E.
    Onteniente, S.
    Jullien, V.
    Montange, D.
    Piedoux, S.
    Thiery-Vuillemin, A.
    Delroeux, D.
    Pili-Floury, S.
    Guardiola, E.
    Combe, M.
    Muret, P.
    Nerich, V.
    Heyd, B.
    Chauffert, B.
    Kantelip, J-P
    Pivot, X.
    BRITISH JOURNAL OF CANCER, 2012, 106 (03) : 460 - 467
  • [7] Elimination of Intravenous Oxycodone in the ElderlyA Pharmacokinetic Study in Postoperative Orthopaedic Patients of Different Age Groups
    Antti Liukas
    Kristiina Kuusniemi
    Riku Aantaa
    Petri Virolainen
    Mikko Neuvonen
    Pertti J. Neuvonen
    Klaus T. Olkkola
    Drugs & Aging, 2011, 28 : 41 - 50
  • [8] A Population Pharmacokinetic and Pharmacodynamic Study of a Peripheral κ-Opioid Receptor Agonist CR665 and Oxycodone
    Anne E. Olesen
    Kim Kristensen
    Camilla Staahl
    Sherron Kell
    Gilbert Y. Wong
    Lars Arendt-Nielsen
    Asbjørn M. Drewes
    Clinical Pharmacokinetics, 2013, 52 : 125 - 137
  • [9] A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups
    Mohmaed Ali, Ma Ida
    Nijstad, A. Laura
    Boosman, Rene J.
    Crombag, Marie-Rose B. S.
    Barnett, Shelby
    Veal, Gareth J.
    Lalmohamed, Arief
    van Erp, Nielka P.
    Steeghs, Neeltje
    Zwaan, C. Michel
    Beijnen, Jos H.
    Siebinga, Hinke
    Huitema, Alwin D. R.
    CLINICAL PHARMACOKINETICS, 2024, : 1711 - 1722
  • [10] Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance
    Korjamo, Timo
    Tolonen, Ari
    Ranta, Veli-Pekka
    Turpeinen, Miia
    Kokki, Hannu
    FRONTIERS IN PHARMACOLOGY, 2012, 2